Nkarta shareholders approve doubling authorized shares; elects Dr. Vratsanos to board

Nkarta, Inc.

Shareholders approved increasing authorized common shares from 100M to 200M.
Elected three Class I directors: Paul Hastings, Angela Thedinga, and new member George Vratsanos.
Ratified Ernst & Young as independent auditor for fiscal 2024.
Press release highlights Dr. Vratsanos' R&D leadership at Jnana, Janssen, Novartis, Roche, BMS.
Nkarta focuses on NK cell therapy for lupus nephritis with NKX019 program.

item 3.03 item 5.03 item 5.07 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.